ration (FILMS) to remove the internal limiting retinal layer from the neural retinal layer at the macula. The method comprises inserting a hollow microcannula between the retinal internal limiting membrane and the neural retinal layer at or near the macula and injecting a Sterile fluid, Such as Sodium hyaluronate, through Said microcannula and thereby raising the macular internal limiting membrane retinal layer away from the neural retina Such that it can then be removed by conventional means, while simultaneously Smoothing the neural retina by localized pressure tamponad. The apparatus comprises a hollow microcannula having a proximal end a distal end and a distal tip. The distal end is shaped to conform tangentially to the Surface of the retina. The distal tip is sharply beveled and adapted to discharge a fluid Substance and to easily insert under the internal limit ing membrane retinal layer and achieve occlusion of the lumen upon minimal insertion, and is Sufficiently micro Scopic as to not Substantially injure the neural retina when introduced under the ILM. 6 Claims, 3 Drawing Sheets Feb. 15, 2000 Sheet 1 of 3 6,024,719 The present invention is directed generally to medical procedures and, more particularly to a medical procedure for removal of the innermost layer of the human retina (internal limiting membrane) from the underlying neural retina at the center of vision (macula).
Background Art
The rays of light entering the eye (FIG. 1) and bearing the pattern of the object being looked upon pass through the cornea 32, the aqueous humor, the pupil, the lens 34, and the vitreous humor, then fall upon the retina 26. The retina is the light sensitive film lining the back two-thirds of the eye. Its appearance is similar to that of wet tissue paper. Its layers consist of the internal limiting membrane (ILM), the neu rosensory retina, and the retinal pigment epithelium; the ILM, being innermost, is the retinal border with the vitreous gel cavity 42. If the parts of the eye are normal and the lens is properly adjusted, the image will be focused upon the retina. This condition results in clear vision. At the back of the eye or, more specifically, the back part of the retina is the macula lutea 36 having at its center the fovea centralis. The macula is a small orange-yellow, oval area (about 3 mm by 5 mm) of the retina adjacent to the optic nerve 38. Vision in which the image of the object looked upon falls upon the macula is the Sharpest Vision and is called macular vision or central vision, as opposed to groSS, peripheral vision.
A wrinkling of the internal limiting membrane and the neural retina is called macular pucker. This can cause loSS of fine vision to the level of legal blindness. The wrinkling is caused by contractile cells or fibrocellular membranes (epimacular proliferation or EMP) and is usually a process asSociated with aging.
Macular distortion and macular edema, with resultant macular dysfunction, are recognized Sequelae of EMP. Often, the macula will have a "wrinkled cellophane' appear ance. According to one theory, this appearance represents internal limiting membrane (ILM) distortion by surface proliferative cells without a distinct epimacular proliferative membrane overlying the ILM, which might be Surgically removed. This ILM cellophaning may persist or occur months after seemingly successful removal of EMP, limiting Visual recovery. Opthalmology, 1990 ). The hem orrhage usually then breaks through the ILM into the Vitreous. Vitreous and Subinternal limiting membrane hem orrhage occurs as a result of abrupt intracranial hemorrhage from an aneurysm or closed head trauma. Although the exact mechanism for these hemorrhages is unknown, it is thought that the Sudden increased intracranial pressure is transmitted via the optic nerve to retinal Venules and capillaries, rup turing them. If bleeding has occurred at the macula, it will appear as a circular or boat shaped cyst (HMC) on the surface of the retina. The HMC is usually encircling the macula. Its diameter and height vary, as does its color, depending on the longevity of the hemorrhage. Early inter vention (i.e., for amblyopia prevention in infants) finds a reddish cyst. A few months after the incident, the Surgeon encounters a yellow lesion (degenerated blood products), a clear membrane Spanning an optically empty cavity, or a collapsed membrane. A perimacular fold may form along the 3 edge of the separation of the ILM from the neurosensory retina at the cyst margin.
Sub ILM hemorrhagic macular cysts are almost pathog nomic to TerSon's Syndrome. Fourteen cases of retinal folds from Shaken baby Syndrome or consequent to direct head trauma were analyzed from various literature reports, each had intracranial hemorrhage and various forms of intraocu lar hemorrhage, including HMC. The HMC's occur not only in traumatically induced cases of TerSon's Syndrome but also in patients with Spontaneous Subarachnoid hemorrhage. Accordingly, it has been proposed that intracranial hemorrhage, from whatever Source, is the common denomi nator in the formation of both HMC's and their accompa nying perimacular folds.
In the cause Severe trauma to the macula and the resultant injury can cause ocular damage of equal Severity to the problem the Surgery is meant to correct.
The current method employed for removal of both EMP and the macular ILM consists of cutting and then grasping, or directly grasping, the macular EMP/ILM with specially designed micro-forceps, 1 mm in maximum diameter, and Slowly pulling it apart from the neural retina. This is done with great care in order to avoid engaging the neurosensory retina.
One problem with the current method of tearing and peeling away the macular ILM is the physical trauma asSociated with pulling on the ILM until it separates thereby unavoidably stressing the underlying nerve tissue, Some times causing irreparable nerve damage with worsened Vision than may have been present preoperatively. Accordingly, the Surgeon may proceed slowly and carefully but if too slowly the retina may be injured from light toxicity coming from the fiberoptic probe inside the eyeball enabling the Surgeon's view. If the Surgeon grasps too shallow then his movements are ineffectual, adding to the time of Surgery and the chance of light toxicity. If the Surgeon grasps too deep, permanent nerve damage and hemorrhage results. The difference is usually a matter of microns of forceps movement, causing the Surgeon's mindset to be what has justly been described as "nerve-wracking." The mass of the forceps, although ever So Small, often obscures the Surgeon's View, further adding to the chance of Surgical damage to the retina. As a result of the above factors, complete traction release is the exception rather than the rule. Finally, even in the unusual case of complete traction release, the nerve tissue will usually require Several months to resume a Smooth contour with best Vision returning. Thus, for Some twenty years, the removal of epimacular proliferation So as to restore central vision in the eyes that are approaching legal blindneSS has remained a Vexing problem for Vitreo retinal Surgeons worldwide. The potential Surgical risks and the uncertain benefits, as well as the high level of skill required to perform Such Surgery has caused many Surgeons to be reluctant to intervene until Vision is Substantially lost. This has been true, despite the knowledge that persistence of EMP causes permanent destruction of nerve function at the center of vision, Such that Visual acuity is only partially restorable, and progressively less so, as the EMP is allowed to persist.
Solutions have been diligently Sought over this twenty year period, including progressively Smaller and finer for ceps. Finally, as an illustration of Surgeons frustration, in 1997, a new concept was introduced by Tano to surgically rub or Scrape the Surface of the retina at or near the macula with a flexible, rubber instrument upon which has been glued innumerable diamond chips. So as to allow the device to purchase a hold on these barely visible membranes and/or ILM. This device was introduced and has been substantially used, despite the obvious risk of damage to the neural retina which underlays these thin membranes by rubbing or Scrap ing the retinal Surface with an intentionally roughened instrument, as well as the risk of diamond chips dislodging and permanently remaining on the retinal Surface within the eye. These risks have been tolerated in the more or leSS desperate Search for effective remedies for traction macul opathy because the device adds an additional means to gain a Surgical edge against the all too frequent need to conclude the operation before achieving complete release of traction.
Wang U.S. Pat. No. 5,066,276, described injecting vis cous material into the eye using a Standard glue injector. Wang, however, did not apply this Surgical procedure within S the retina itself. Rather, Wang described injecting the vis cous material between a glia cell membrane and the retina. Wang described his procedure as one in which the pressure applied to the retina is very diffuse and not localized in one Small area in order to reduce Stresses on the retina.
There remains a need for improved methods for removal of both epimacular proliferations and the abnormal ILM of the retina to completely relieve all forms of traction macu lopathy in which the ILM is contributory. Such a method must be based upon minimizing Surgical traction on the underlying nerve tissue at the center of vision (fovea). The method and apparatus described herein overcomes the above noted problems.
SUMMARY OF THE INVENTION
The present invention provides a novel method for per forming Surgery inside the human retina using fluidic ILM Separation (FILMS) and Simultaneous retinal Smoothing to overcome the disadvantages of the previously known meth ods.
Briefly, the present invention is directed to a method of Separating the ILM layer of the retina from the neural layer of the retina in order to remove the macular internal limiting membrane and all EMP on its Surface. The method com prises inserting a hollow microcannula, considerably Smaller than any Such cannula heretofore, which is shaped at its distal end to conform tangentially to the Surface of the retina, between the retinal ILM and the neural retina. After the microcannula is inserted, a Sterile fluid is injected at a preSSure of about 25 mm Hg through the microcannula between the ILM layer of the retina and the neural layer of the retina. The fluid pressure lifts the macular internal limiting membrane layer away from the neural layer of the retina, Separating it in the process of lifting away and allowing for its easy forcepS removal from the eye without inflicting any physical trauma upon the neural retina. The lifted macular internal limiting membrane is removed by grasping the free-floating macular internal limiting mem brane with forceps and extending the macular internal limiting membrane Separation as distant from the fovea as desired before tearing circumferentially about the fovea and removing from the eye. The present invention allows for the removal of the macular internal limiting membrane without mechanically peeling or tearing it away from the fovea, So as to minimize foveal traction and the resultant physical trauma to the fovea. Moreover, the present invention Simul taneously actively Smoothes the underlying distorted and Wrinkled neural retina by an intentional build-up of localized pressure within the confines of the developing FILMS cyst of which it is the posterior border. Thus, visual recovery, the ultimate Surgical goal, is Substantially accelerated as com pared to the months needed for passive, Spontaneous retinal Smoothing after forceps traction removal. The preferred Substance for use in practicing the invention and achieving complete removal of the macular internal limiting mem brane is Sodium hyaluronate (Healon(R), as manufactured by Pharmacia & Upjohn Inc. or chondroitin Sodium hyalur onate (Viscoat(R) as manufactured by Alcon, Inc.
The present invention allows Surgeons to operate, for the first time, inside the human retina (intraretinal) rather than above its Surface. In So doing, it enables the Surgeon to gently, predictably, and rapidly remove the ILM and all EMP adhered to the neural retina. The gentleness of the invented method eliminateS risk of mechanical traction from pulling on the nerve fibers. The speed of the method, typically 4 minutes as opposed to 15 minutes, Substantially reduces the risk of light toxicity. The predictability of the method allows for a more certain benefit from the Surgery. Moreover, the method affords a significant decrease in the Surgical skill level needed to treat traction maculopathy and makes visual recovery more rapid, more certain, and more complete. The Sum effect is to enable patients Suffering Visual loSS due to traction maculopathy of any type to Seek and find earlier and more certain relief from distorted and reduced Visual acuity, while the associated neural retinal abnormality is still revers ible.
It is the principle object of the present invention to provide an improved method for macular ILM removal and retinal Smoothing. Other objects and advantages of the present invention will become readily apparent from the following detailed description taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
A better understanding of the present invention will be had upon reference to the following detailed description when read in conjunction with the accompanying drawings.
FIGS. 1 and 2, previously discussed, show the prior art. limiting membrane (ILM) by the production of a circular, 360 ILM tear concentric with the fovea, while minimizing foveal traction. This procedure is used to relieve all forms of traction maculopathy in which the ILM is contributory, as a result of its innate inelasticity or its action as a Scaffold for fibrocellular proliferation (EMP).
"Traction Maculopathy' is a pathological dysfunction of the macula partially or entirely Secondary to abnormal tangential or anteroposterior forces (e.g. macular hole, epe imacular proliferation, Vitreomacular traction Syndrome, dif fuse diabetic macular edema, cellophane maculopathy).
"Fluid" is a substance whose molecules move easily acroSS one another; a liquid or a gas.
"Neural Retina' is the middle layer of the retina, between the ILM and the pigment epithelial layers, which is com posed of nerve tissue and which generates and transmits the electrical Signals ultimately recognized as Vision.
Preferred Embodiments
Disclosed herein is a novel procedure allowing Surgery within the human retina to remove the internal limiting membrane utilizing fluidic Separation. With reference to  FIG. 4 , to begin the process of ILM removal, an optimal Starting point is chosen within the arcade vessels but remote from the fovea. Additionally, the chosen Starting point Site should not overlie the papillomacular bundle. Furthermore, the Starting point is Selected on the basis of the appearance of the ILM, and for Surgical convenience. In a preferred embodiment, referring to FIG. 3 The free-floating raised macular ILM 22 is then grasped by forceps. When the forceps are then used to grasp the macular ILM 22 separated from the surface of the retina 26, the maneuver becomes predictable and non-traumatic because there is no need to tear or peel the macular ILM 22 away from any direct adhesion to the fovea and Surrounding macular Surface of the retina 26, eliminating any vertical or tangential force vectors as placed upon the fovea by forceps ILM removal, Substituting in its stead a very gentle and precisely controlled tamponad pressure. Then, a (Smooth edged continuous tear) "rhexis" is created by slowly tearing the ILM in a circular pattern concentric with the fovea, at a distance from the fovea as Selected by the Surgeon after further mechanical stripping of the ILM beyond the macular FILMS cyst. A surgeon can often create the complete 360 rhexis in one motion. However, if the tear is incomplete, the ILM is simply regrasped at the new edge, and the rhexis is resumed.
The problem of adhesion and the necessity to tear and peel the macular ILM from the surface of the retina (fovea and macular center of vision) and the resultant physical trauma impressed upon these areas is completely avoided. By injecting a fluid Substance within the retina tissue, the macular ILM is Separated from contact with the neural retina prior to grasping and removing it from the retina. Therefore, the macular ILM is never actually torn or peeled away from the retina and there is no physical trauma caused by adhesion of the macular ILM to the neural retina because the injected fluid lifts the membrane away from the surface of the retina before it is removed using the forcepS.
While embodiments and applications of this invention have been here shown and described, it would be apparent to those skilled in the art that many more modifications are possible without departing from the inventive concepts herein. The invention, therefore, is not to be restricted except in the Spirit of the appended claims.
EXAMPLES
It must be noted that as used herein and in the appended claims, the singular forms "a" "and" and "the' include the plural references unless the context clearly dictates other wise. Thus, for example, reference to "a formulation" includes mixtures of different formulations and reference to "the method of treatment" includes reference to equivalent StepS and methods known to those skilled in the art, and So forth.
Unless defined otherwise, all technical and Scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials Similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described. All publications mentioned herein are fully incorporated herein by reference.
What is claimed is:
1. A method for performing Surgery inside a human retina using fluidic internal limiting membrane Separation com prising:
inserting a hollow microcannula between a neural retina and a retinal internal limiting membrane at or near a 2. The method of claim 1, wherein said sterile Substance is Sodium hyaluronate.
3. The method of claim 1, wherein said sterile Substance is injected with or without a dye.
4. The method of claim 1, wherein said hollow micro cannula has a distal end and a proximal end, and Said microcannula is shaped at its distal end to conform tangen tially to the Surface of a retina near a macula while inserted from an eye wall entry Site at the parS plana, and is adapted at the distal tip to discharge Said Sterile Substance from the distal tip of the microcannula, and to allow easy entry through an internal limiting membrane of a retina and optimal occlusion of the microcannula lumen by an overly ing internal limiting membrane when minimally introduced, and in which Said microcannula is So microscopic as to not Substantially injure a neural retina when introduced under an ILM.
5. The method of claim 1, wherein said sterile Substance is an isotonic Saline Solution.
6. The method of claim 1, wherein said sterile Substance is a gas.
